TAVR for Aortic Valve Disease

NCT05439863 · tracked via the Priya Life Science China tracker

Sponsor

Nanjing First Hospital, Nanjing Medical University

Phase

Observational

Started

2022-07-01

Last updated

2024-11-15

Condition(s) studied

Aortic Valve Disease

Investigational drug(s) / intervention(s)

transcatheter heart valve

transcatheter heart valve: patients with severe aortic valve disease underwent transcatheter heart valve

Study summary

Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Clinical diagnosis of severe aortic stenosis or aortic regurgitation 2. Patients undergo transcatheter aortic valve replacement Exclusion Criteria: patients refuse the clinical follow-up

Primary outcome measure(s)

all-cause death during follow-up — 5 years
all-cause death during 5-year follow-up

Trial sites (1)

Facility	City	Region	Status
Nanjing First Hospital	Nanjing	Jiangsu	Recruiting

More Nanjing First Hospital, Nanjing Medical University trials in China

Predictors and Clinical Outcomes of Patients With Coronary Heart Disease Co-morbid Depression Post Percutaneous Coronary Intervention Active, not recruiting

Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome Recruiting

The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM). Starting soon

National Registry and Cohort Study of Pulmonary Vascular Disease Recruiting

Application of CLCVP Technique in Early Intervention of CSA-AKI Recruiting

Other trials for the same condition

Evaluating the Safety and Efficacy of Prosthetic Polymer Heart Valves for the Treatment of Aortic Valve Disease Enrolling by invitation

Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction Recruiting

Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation Recruiting

VitaFlow® Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up （VITAL） Starting soon

Prospective Observational Cohort Study of Moderate Aortic Valve Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05439863 on ClinicalTrials.gov ↗ ← All trials in China